Senior Vice President, Chief Scientific Officer
Sy Pretorius is the Chief Scientific Officer at PAREXEL and has been with PAREXEL for the past twenty years in a variety of roles and countries. On a day-to-day basis, Dr. Pretorius collaborates closely with biopharmaceutical and medical device clients in designing and optimizing drug / device development strategies and plans, as well as finding, evaluating and purchasing assets. Dr. Pretorius is responsible for the overall leadership of a number of PAREXEL business units – these include our global Early Phase business (responsible for Phase I and II clinical development), Global Medical Services (therapeutic area expertize, global medical writing and pharmacovigilance operations), Quantitative Clinical Development (modeling and simulation), as well as the Genomic Medicine unit. Dr. Pretorius is absolutely passionate about drug development and leads several company-wide forums and initiatives focused on clinical trial innovation and further expanding PAREXEL’s capabilities and service offering. Dr. Pretorius is a Medical Doctor (M.B.,Ch.B) with Masters degrees in Clinical Pharmacology (M.Med.Sc), Business Administration (MBA) and, most recently in the Management of Drug Development (MS) from the University of Southern California (USC). Dr. Pretorius has and continues to publish and present extensively.